| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Analyst/Investor event showcases opportunities for KO-2806 (darlifarnib) in combination with PI3Kα inhibitors, KRAS inhibitors and antiangiogenic tyrosine kinase inhibitors (TKIs)
Preliminary clinical data and KO-2806 development plans to be presented in October 2025 in conjunction with the ESMO Congress 2025
SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today is hosting the first of two analyst/investor events focused on its farnesyl transferase inhibitor (FTI) program. The session features compelling preclinical data illustrating the potential of FTIs to address a common resistance pathway, thereby enhancing the anti-tumor activity of PI3Kα inhibitors, KRAS inhibitors and antiangiogenic tyrosine kinase inhibitors (TKIs) across a range of diverse tumor types. These findings, drawn from Kura's pioneering research on FTI mechanisms, offer important context to interpret the preliminary clinical data to be presented next month at the ESMO Congress 2025.
Posted In: KURA
